Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers
详细信息 查看全文
- 作者：Kristen E. Mullera ; Jonathan D. Marottia ; Francine B. de Abreua ; Jason D. Petersona ; Todd W. Millerb ; Mary D. Chamberlinc ; Gregory J. Tsongalisa ; Laura J. Tafea ; Laura.J.Tafe@hitchcock.org" class="auth_mail" title="E-mail the corresponding author
- 关键词：Breast cancer ; Next-generation sequencing ; Targeted therapy ; Metastatic cancer ; Somatic mutations
- 刊名：Experimental and Molecular Pathology
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：100
- 期：3
- 页码：421-425
- 全文大小：412 K
文摘
- •
In this study we identified potentially actionable somatic mutations in metastatic breast tumors using the Ion AmpliSeq™ Cancer Hotspot Panel v2.
- •
Twenty-two cases were sequenced, and 28 variants in 11 of the 50 genes analyzed were observed; an average of 1.7 variants per tumor.
- •
The most commonly altered genes included TP53, PIK3CA, APC, MET, and ERBB2.
- •
Metastatic breast cancer is genetically diverse and the majority of metastatic breast tumors harbor potentially actionable mutations.
- •
NGS of metastatic breast cancer provides a useful modality to characterize metastatic breast cancer on an individualized basis.